4D Molecular Therapeutics, Inc.

US$12.25As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:FDMTHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (18.80%)
Div yield —
ROE (43.25%)
Biotechnology
Beta (5Y) 2.91
PE TTM —
TSR TTM 6.52%
Mkt cap US$676.7M
ROIC (27.21%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$12
1.72%
(36.41%)
Hold 4|2|1|1|9
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.20
0.21
0.21
0.21
44.66%
35.77%
20.08%
14.84%
Revenue$M
43.33
42.64
41.97
41.77
9.32%
1.73%
(1.07%)
0.24%
Peers (US$676.7M)
Cap (US$)
PE
681.7M
26.80x
Capital
TTM
5Y
10Y
Leveragex
7.245
0.023
0.021
EBIT/Intx
1.101
0.220
0.208
Own earn%
(0.89)
22.05
33.24
Sh yield%
24.19
3.19
5.45
Owners
Insiders/Inst%
8.82
26.63
Short interest%
3.03
SBC / revenue%
4.63
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
22–28
$1 testx
0.1
Incr. ROIC%
40